Same reason as other strategies/tactics are not explained to the market. They don't want regulators etc reading their releases as that could make negotiating favourable regulatory outcomes more difficult. Its not really a good strategy anymore if everyone knows about it...
It's really up to the investor to see that this is a very well run company, and to back the management team who clearly know what they're doing.
Ann: SCENESSE European Orphan Drug Designation for VP, page-13
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.11 |
Change
0.240(1.73%) |
Mkt cap ! $703.3M | |||
| Open | High | Low | Value | Volume |
| $13.90 | $14.15 | $13.90 | $487.2K | 34.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 55 | $14.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.15 | 1480 | 1 |
View Market Depth
| Last trade - 13.33pm 11/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |